
Paul R Becherer MD
Assistant Consulting Professor in the Department of Medicine, Duke University
Join to view full profile
2304 Wesvill CtSuite 240Raleigh, NC 27607
Phone+1 919-571-1567
Fax+1 919-782-1472
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul Becherer, MD is an infectious disease specialist in Raleigh, North Carolina. He is currently licensed to practice medicine in North Carolina. He is an Assistant Consulting Professor in the Department of Medicine at Duke University.
Education & Training
University of North Carolina HospitalsFellowship, Infectious Disease, 1987 - 1990
University of North Carolina HospitalsResidency, Internal Medicine, 1983 - 1987
University of Illinois College of MedicineClass of 1983
Certifications & Licensure
NC State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013-2017
- CMS Meaningful Use Stage 2 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013-2017
Publications & Presentations
PubMed
- 10 citationsThe use of 3.15% chlorhexidine gluconate/70% alcohol hub disinfection to prevent central line-associated bloodstream infections in dialysis patients.R. Marty Cooney, Nisha Manickam, Paul Becherer, Laura S. Harmon, Liza Gregg
British Journal of Nursing. 2020-01-23 - 76 citationsEffectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: ...Deverick J. Anderson, Rebekah W. Moehring, David J. Weber, Sarah S. Lewis, Luke F. Chen
The Lancet. Infectious Diseases. 2018-06-04 - 245 citationsEnhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal ...Deverick J. Anderson, Luke F. Chen, David J. Weber, Rebekah W. Moehring, Sarah S. Lewis
Lancet. 2017-02-25